Lesko LJ, Woodcock J.Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective . Nat Rev Drug Discov. 2004;3(9):763.
2.
Weinshilboum RM, Wang L.Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Human Genet.2006;7(1):223-245.
3.
Rihs H-P., John A., Scherenberg M., Seidel A., Bruning T.Concordance between the deduced acetylation status generated by high-speed real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. Clin Chim Acta. 2007;376(1-2):240.
4.
Heim M., Meyer UAGenotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification . Lancet. 1990;336(8714):529-532.
5.
Frueh FW, Rudman A., Simon K., Gutman S., Reed C., Dorner AJExperience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J. 2006;6(5):296-300.
